Fierce Biotech on LinkedIn: Fierce Biotech Layoff Tracker 2023: Reneo reduces workforce by 70%;… (2024)

Marea Therapeutics has emerged with $190 million, a mid-stage clinical program and a plan to pioneer “the next frontier” of cardiometabolic medicines.

30

1 Comment

Roche has added to its flotilla of RNA alliances, handing Ascidian Therapeutics $42 million upfront to use an alternative to gene editing to treat neurological diseases. The agreement includes up to $1.8 billion in milestones.

43

1 Comment

Sanofi is offering Belharra Therapeutics up to $700 million in biobucks for a tow out to surf the waves of small molecule drug discovery in immunology.

42

1 Comment

The FDA is joining hands with regulators in Canada and the U.K. on policies to ensure transparency in the development of medical devices powered by machine learning.

14

Data presented at the EHA 2024 meeting show Gilead's now-abandoned CD47 drug magrolimab failed to deliver.

6

1 Comment

Takeda’s late-phase epilepsy program hasfaileda key test, chalking up misses on the primary endpoints in pivotal trials in two indications. But the drugmaker still plans to talk to regulators about the next steps for the Ovid Therapeutics-partnered prospect.

11

1 Comment

Cabaletta Bio’s shares tumbled 13% Friday morning as the biotech shared just a crumb of data from two patients in an autoimmune CAR-T trial that hinted at remission.

11

1 Comment

Investors celebrating the summer resurgence of biotech IPOs might want to put the champagne back on ice, after Telix Pharmaceuticals made thelast-minute decisionto pull its own Nasdaq listing.

28

1 Comment

Pfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor function for boys with duch*enne muscular dystrophy. The news "all but removes" the asset from the competitive DMD landscape as Sarepta'sElevidys awaits an FDA decision, according to William Blair analysts.

41

Foresite Capital CEO Jim Tananbaum says we’re in “one of the best biotech investment environments” of his multidecade career—and has rounded up $900 million to put that belief to the test with a fresh set of big bets.

51

3 Comments